Company

SanReno Therapeutics Limited

SanReno Therapeutics develops drugs for chronic kidney disease and related conditions.

About

Founded in 2021, SanReno Therapeutics is based in China and researches and develops treatments for kidney disease. Its products include Atrasentan and Zigakibart (BION-1301), for IgA nephropathy and other proteinuric glomerular diseases. In November 2021, it raised USD 40 million co-led by Frazier Healthcare Partners and Pivotal Life Sciences, with Samsara BioCapital and Versant Ventures participating. Novartis fully acquired the company in January 2022.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in